Moreover, enzalutamide, a widely applied anti-androgen therapy in advanced prostate cancer, has been found to suppress EPHB6 expression by binding to the androgen-response-element on the EPHB6 promoter to stimulate tumor cell metastasis (55). Here, EPHB6 is linked to prostate carcinoma.